top of page

Search Results

Results found for "GPCR Therapeutics"

  • How Schild Analysis Protects Your Conclusions in GPCR Research

    Listen to the episode ➤ Quick Links Assess GPCR Biased Signaling of Agonist How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling GPCR Premium Membership Gives You an Edge Premium delivers a clear, noise-free stream of GPCR intelligence GPCR innovation is accelerating. GPCR Team

  • How a Failed Med School Dream Sparked a GPCR Biotech Revolution

    But for Ajay Yekkirala, that closed door lit the fuse for a career that would reimagine GPCR therapeutics therapeutics. therapeutics. Blue Therapeutics: Turning GPCR Biology Into a Business Ajay’s academic training planted the seeds for therapeutics.

  • 📰 GPCR Weekly News, October 23 to 29, 2023

    Hi there GPCR minds! Join us for a deep dive into the world of GPCRs. This week's highlight: Congratulations to the GPCR Therapeutics team for their publication on improving GPCR Symposium for the year on GPCRs in Immunology and Oncology! Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol Progress Parker Moss to Join Exscientia as EVP, Corporate Development Confo Therapeutics Nominated for

  • Dr. GPCR Spotlights Revvity’s pHSense™ Internalization Tools

    GPCR , the global nonprofit platform dedicated to advancing GPCR science through education, community GPCR Ecosystem. GPCR Podcast To mark the spotlight, Dr. GPCR  invited Dr. Eric Trinquet  to the Dr. GPCR. GPCR Dr.

  • Posttranslational modifications in GPCR internalization

    August 2022 "G protein-coupled receptors (GPCRs) are the largest family of membrane receptors that serve Classically, GPCR internalization has been considered to lead to receptor desensitization. Here, this review summarizes different PTMs in GPCR internalization and analyzes their significance in , which will offer new insights into the regulatory mechanism of GPCR signaling and novel drug targets Read more at the source #DrGPCR #GPCR #IndustryNews

  • A Note from Yamina: Building the Next Chapter of Dr. GPCR

    GPCR. Dear Dr. GPCR, it was with a simple goal: to connect people who shared a passion for GPCR science and discovery GPCR Foundry  — our R&D and biotech hub designed to bridge GPCR science with execution. The Dr. GPCR resources, connect new scientists, and earn rewards  for helping expand access to GPCR knowledge GPCR About Dr. GPCR Dr.

  • Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for ...

    July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases "29/06/2022 Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates . " Read more at the source #DrGPCR #GPCR #IndustryNews

  • Illuminating the draggable GPCR-ome

    GPCR Virtual Cafe. This time with none other than Dr. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

  • Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?

    In the high-stakes world of GPCR drug discovery , breakthrough science isn't enough. GPCR, we recognized this core problem. This is the essence of de-risking GPCR programs through operational excellence. the entire GPCR program as a single, interconnected entity. The GPCR Precision Blueprint is more than a concept.

  • Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal

    Why Speed Matters in GPCR Drug Discovery Nine out of ten GPCR programs stall  not because the target In accelerating GPCR drug discovery, the bottleneck isn’t target identification — it’s turning validated “GPCRs are nature’s prototype allosteric proteins. Everything they do is allosteric.” Antibodies, Bias, and the Expanding Modality Landscape Antibody therapeutics are now entering spaces Kenakin with your own enzyme or GPCR interaction puzzles.

  • 📰 GPCR Weekly News, September 11 to 17, 2023

    Hello GPCR people! Check out our GPCR roundup now, and be the first to read! Kevin Wright on his new position as Director of Targeted and Immuno-oncology at GPCR Therapeutics, our GPCR Symposium on 'GPCRs as Therapeutic Modalities' with Richa Tyagi, Dr. Terry Kenakin, Dr. Kevin Wright Joins GPCR Therapeutics as Director of Targeted and Immuno-oncology Sosei Heptares Adds Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

  • 📰 GPCR Weekly News, August 14 to 20, 2023

    Congrats to the GPCR Therapeutics team for their recent paper in the American College of Clinical Pharmacology GPCR Symposium on 'GPCRs as Therapeutic Modalities'. and oligomerization Molecular Insights into GPCR Mechanisms for Drugs of Abuse Industry News 'GPCR Therapeutics Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic Antibodies Using AI ONCORNET2.0 GPCR Ecosystem

  • 📰 GPCR Weekly News, June 19 to 25, 2023

    GPCR Partner, GPCR Therapeutics, for passing the Technology Evaluation process for listing on the KOSDAQ GPCR Symposium on Structural and Molecular Insights on GPCR Activation. GPCR Therapeutics passes the Technology Evaluation process for listing on KOSDAQ. " (June 28 - 30, 2023) FREE Seminar Antibodies targeting Membrane Proteins - From Antigen to New Therapeutics GPCR Ecosystem

  • 📰 GPCR Weekly News, December 11 to 17, 2023

    This week's highlights: Kudos to our partner, GPCR Therapeutics, for partnering with Bridge Biotherapeutics Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis - Providing the next generation of high-impact medicines Structure Therapeutics Provides Comprehensive Study Neurocrine opening two Phase 1 trials in oral Parkinson’s therapies Bearing Fruit: Deep Apple Therapeutics Launches to Screen AI-Generated Virtual Libraries AbbVie to Acquire Cerevel Therapeutics in Transformative

  • Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence

    Strategies for Targeted Therapeutics. GPCR-Based Drug Discovery conference is where the future of GPCR therapies will be defined. GPCR Premium Membership Gives You an Edge In a world filled with noise, Dr. GPCR Premium Membership delivers curated, noise-free intelligence every week. The pace of GPCR innovation is accelerating.

  • How a Failed Experiment Created a Powerful GPCR Imaging Tool

    Broichhagen aka JB, the goal was bold and elegant: Create a photo-switchable ligand to remotely control GPCR They had a tool that did bind the GPCR… but not in the light-controlled way they wanted. not just the pancreas This tool helped clarify: Which neurons respond Which cell populations drive therapeutic The Larger Lesson for Scientists and Innovators This story isn’t just about a GPCR imaging tool. metabolic therapy Guide how next-generation incretin drugs are designed Support cell-targeted conjugate therapeutic

  • Mechanism vs. Assumption: A Model-First Path to Getting GPCR MoA Right

    Fluorescent probes illuminate the mysteries of GPCRs in cutting-edge research. Hi GPCR Community, If you work on GPCR discovery, you already know: early signals can mislead, and timing GPCR Premium: Sneak Peek A fast, editorial preview—enough to guide your attention, not replace your due Track, GPCR Happy Hour, and more! GPCR innovation is accelerating.

  • Enhancing GPCR Research Outreach | Dr GPCR University early-bird registration ends soon!

    We've got 11 GPCR papers, seven industry news pieces, a new GPCR event, and even a job ad.   for Drug Discovery DMS: Linking Protein Structure To Function AbbVie Completes Acquisition of Cerevel Therapeutics Nxera Pharma attended the Drug Discovery Ecosystem Summit Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million Tectonic Therapeutic Announces GPCR Ecosystem

  • Unlocking the Therapeutic Potential of Previously Undruggable GPCRs

    A New Wave of GPCR Drug Discovery GPCRs are considered highly druggable, with GPCR-targeting therapeutics Within the last two years, three investments stand out: · Tectonic Therapeutics: received $80 Domain Therapeutics: completed a $42 Million USD Series A round to develop novel immunotherapies, including Developing Small Protein Therapeutics with a Novel Discovery Platform One way to overcome the challenges About Orion Biotechnology Orion’s mission is to unlock the therapeutic potential of previously undruggable

  • The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology

    his interview, Regulators of G protein Signaling (RGS proteins)  might hold some of the most untapped therapeutic explicitly interested in GPCR signaling... but the thing about GPCRs... is you always kind of end up landing at a GPCR as a major target." GPCRs in the Background, But Always Present Even though his primary focus wasn’t GPCRs themselves, Serafini Takeaway Forget what you think you know about GPCR drug targets.

  • Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools

    GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, is proud therapeutics. GPCR. accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic GPCR Dr.

  • How Advanced GPCR Kinetics Sharpen Decision Making (and Save You Time)

    Exploring the Hidden Dynamics: How Kinetics Reveals What Equilibrium Conceals in GPCR Research. Hi GPCR Community, If equilibrium curves are your comfort zone, this week’s feature will challenge (and GPCR Premium: Sneak Peek Here’s a fast, high-level preview of what Premium Members are unpacking this We’ve got your GPCR Track, Happy Hour, and sessions mapped so you can extract maximum value. GPCR innovation is accelerating.

  • Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox

    For decades, GPCRs have been the cornerstone of pharmacology. GPCR Modeling in Context: Then and Now When Carlsson entered the GPCR field in the early 2000s, structural Why Predictive GPCR Modeling Matters Now The convergence of machine learning, improved GPCR structures Want to go deeper into GPCR modeling? Dr. GPCR Podcast Push the boundaries of what's possible 👉 Join the Dr.

  • GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions

    Welcome back GPCR fans, If your drug discovery strategy still relies on static GPCR models, you’re already Upcoming events:  GPCR-UK Network Meeting, neuroGPCR symposium, and Transatlantic ECI GPCR event—where Leverage this model to stay ahead of therapeutic complexity. GPCR Podcast Listener Why Dr. GPCR Premium 🔹 What’s included?

  • Mark Schmeizl - Dr. GPCR Podcast

    GPCR podcast is now available! Our guest is Mark Schmeizl! Listen where you get your podcasts https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ #drgpcr #gpcr #podcast

  • How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights

    GPCR Premium: Sneak Peek Want the full classified brief? GPCR , our mission is simple but urgent: Accelerate GPCR biology and drug discovery by connecting scientists GPCR Podcast, the Revvity team built pHSense™ from the ground up by listening to what GPCR scientists GPCR innovation is accelerating. GPCR and the offered resources in my work sphere." — DrGPCR University Attendee GPCR innovation doesn

  • Join the #GPCR movement today!

    GPCR Ecosystem paid membership with extra benefits? 🔬Join the #GPCR movement today! ➡️ https://www.ecosystem.drgpcr.com/plans-pricing #gpcr #drgpcr

  • Single-molecule counting applied to the study of GPCR oligomerization

    Read more at the source #DrGPCR #GPCR #IndustryNews

  • Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology

    In GPCR drug discovery, a single mistaken assumption can derail an entire program. Why Misreading Antagonism Delays GPCR Drug Discovery If a dose-response curve shifts to the right, you Why now:  GPCR research is accelerating—and the projects that succeed will be those built on clear, accurate

  • Community guidelines for GPCR ligand bias: IUPHAR review 32

    August 2022 "GPCRs modulate a plethora of physiological processes and mediate the effects of one-third Read more at the source #DrGPCR #GPCR #IndustryNews

bottom of page